Patents Assigned to GREYLEDGE TECHNOLOGIES, LLC
  • Publication number: 20250369838
    Abstract: A system and method are disclosed that allows for the standardization of the application of physical force during microfragmentation of adipose tissue with enhanced sterility. A method is also disclosed that enables an accelerated digestion of a portion of the microfragmented adipose tissue that allows for at least an estimation of the viability of the released cells, as well as a particle/cell count. A further method is disclosed to provide for assessing attributes of the microfragmented adipose tissue, including physical, biochemical and metabolic characteristics of particles/cells present in and/or isolated from the microfragmented adipose tissue.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 4, 2025
    Applicant: Greyledge Technologies, LLC
    Inventors: David Karli, Theodore Sand, Mark Kitchen, Robert Jones
  • Patent number: 11340212
    Abstract: Methods of analyzing a biological fluid to determine an expected therapeutic benefit of the fluid include determining amounts of components within the biological fluid. Comparisons of a first component of the biological fluid relative to another component of the biological are made to characterize a therapeutic effect of the biological fluid.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: May 24, 2022
    Assignee: Greyledge Technologies, LLC
    Inventors: David Karli, Theodore Sand
  • Patent number: 9840690
    Abstract: An autologous cell concentrating system and method are disclosed. The system has a blood separation component, a first vessel, a second vessel, a first valve, a second valve, and a concentration and flow logic and control component. The concentration and flow logic and control component is configured to: determine a first volume of a target cell-poor fraction in the first vessel to mix with a target cell-rich fraction in the second vessel in order to form a target cell-rich concentrate having a concentration of target cells that is within a target concentration range; and control the second valve to transfer the first volume of the target cell-rich fraction from the first vessel to the second vessel to form the target cell-rich concentrate. The target concentration range is between 1.0 and 1.5×106 target cells/?L.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: December 12, 2017
    Assignee: Greyledge Technologies, LLC
    Inventors: David Karli, David L. Bombard
  • Publication number: 20120237490
    Abstract: This disclosure describes systems, methods, and apparatus for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and/or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and/or volume.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: GREYLEDGE TECHNOLOGIES, LLC
    Inventors: David Karli, David L. Bombard